Material Overview: Properties of Glass and Plastic in Pharma

Glass: Glass, particularly Type I borosilicate, is chemically inert, impermeable, and thermally stable. It’s widely used in parenteral packaging and products with high sensitivity.

Plastic: Common plastics include HDPE, PET, and PP. They offer lighter weight and better resistance to breakage but are more permeable to gases and moisture.

• Glass is suitable for high-risk, injectable formulations
• Plastic is preferred for solid or oral liquid dosage forms

Chemical Compatibility and Reactivity

One of the most critical selection criteria is the interaction between the container and the drug product. Glass is non-reactive but may release trace alkali (in Type II or III) in some conditions. Plastic, on the other hand, may:

• Leach additives (plasticizers, antioxidants)
• Absorb or adsorb active ingredients
• React with solvents or volatile excipients

Compatibility studies are essential regardless of the material type. Testing should include leachables, extractables, and sorption assessments.

Barrier Properties: Moisture and Oxygen Transmission

Moisture ingress and oxygen permeability are major concerns during long-term storage.

• Glass: Offers complete barrier protection against water vapor and oxygen
• Plastic: Materials like HDPE have relatively high WVTR (water vapor transmission rate), while PET has better barrier properties

For sensitive formulations, glass or multilayer plastic with barrier coatings is preferred. Use appropriate desiccants in plastic packaging to reduce moisture uptake risk.

Mechanical Durability and Breakage Risk

Glass is fragile and prone to breakage during transport or handling, especially in high-speed filling lines or drop tests. Plastic is:

• Impact-resistant
• Lighter in weight
• Less costly to ship and store

For pediatric, geriatric, or field-use products, plastic often enhances patient and packaging safety.

Photostability and Light Protection

Amber glass provides high UV protection, making it ideal for photolabile drugs. In contrast:

• Plastic may need additional pigments or UV-blocking agents
• Opaque polymers (like black HDPE) are used when UV exposure is critical

Ensure ICH Q1B photostability testing is performed with final container type to evaluate light-related degradation risk.

Case Study: Vitamin Solution in PET vs. Glass

In a comparative study, a multivitamin oral solution stored in PET bottles showed 7% degradation at 3 months (40°C/75% RH), while the same product in amber Type I glass retained 98% potency. The oxygen permeability of PET contributed to oxidative degradation. Result: manufacturer switched to glass for final packaging.

Regulatory Expectations and Submission Impact

According to CDSCO and ICH, packaging used in stability must reflect the marketed pack. Regulatory agencies expect:

• Extractables and leachables studies for plastic
• Glass delamination risk assessment (for glass)
• Material specification sheets and compliance (e.g., USP for plastic)
• Photostability, integrity, and aging data

Failure to justify container type can delay approvals or prompt deficiency letters.

Environmental Impact and Sustainability Considerations

As sustainability becomes a regulatory and market priority, container material choice also reflects environmental responsibility.

• Glass: 100% recyclable, inert, and reusable—but energy-intensive to produce
• Plastic: Lower energy production cost but may generate microplastics and requires recycling infrastructure

Some companies opt for bio-based plastics or recyclable HDPE as a sustainable alternative when stability allows.

Cost and Supply Chain Factors

Cost can be a deciding factor when technical performance is equivalent:

• Plastic containers generally cost less in manufacturing and transportation
• Glass containers require specialized handling, packaging, and higher QA oversight
• Long lead times and regional supply dependencies can affect availability of both materials

Balance between cost and compliance is essential—cutting costs at the expense of protection often leads to regulatory delays.

When to Use Glass Over Plastic

• Parenteral dosage forms
• Highly moisture- or oxygen-sensitive APIs
• Long shelf-life products requiring complete barrier protection
• Regulatory submissions where robust data is essential

When Plastic Is a Better Choice

• Oral liquids or tablets with moderate sensitivity
• Patient-friendly packaging needs (e.g., squeezability, safety)
• Field or ambulatory settings with rough handling
• Cost-sensitive generics or short-shelf-life products

Stability Study Design: Considerations for Both Materials

Whether using glass or plastic, follow these best practices:

• Test containers under ICH long-term and accelerated conditions
• Include photostability and CCI tests in validation
• Conduct migration and sorption studies
• Ensure sealing compatibility with closures
• Perform mechanical testing under simulated transport stress

Refer to GMP guidelines to align packaging qualification with regulatory expectations.

Summary Comparison Table

Conclusion

Choosing between glass and plastic containers for long-term pharmaceutical storage requires a nuanced understanding of product properties, regulatory expectations, and logistical challenges. While glass offers unmatched protection and regulatory acceptance, plastic provides practical benefits in cost and safety. The right decision depends on balancing technical performance with compliance, sustainability, and patient use requirements.

References:

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• USP : Plastic Packaging Systems
• USP : Assessment of Extractables
• FDA Guidance for Industry: Container Closure Systems
• WHO Guidelines on Packaging Materials for Pharmaceuticals

Assessing Packaging Material Interaction During Long-Term Pharmaceutical Storage

Pharmaceutical packaging is not just a passive container; it plays an active role in maintaining product integrity over its shelf life. During long-term storage, interactions between packaging material and the drug product can lead to degradation, contamination, or performance loss. Regulatory guidelines from ICH, FDA, EMA, and WHO emphasize the importance of assessing container-closure systems as part of stability studies. This guide explores how pharmaceutical professionals can evaluate and mitigate packaging-related risks during long-term storage under real-time and intermediate conditions.

1. Why Packaging Interaction Matters in Stability Studies

Packaging material is in constant contact with the pharmaceutical product, especially for oral liquids, injectables, and inhalers. Over time, this can lead to:

• Migration of leachables into the product
• Permeation of moisture, oxygen, or light into the container
• Physical degradation of seals, laminates, or adhesives
• Adsorption of APIs or excipients onto container surfaces

Consequences Include:

• Loss of potency due to oxidation or hydrolysis
• Formation of impurities due to interaction with closure materials
• Incompatibility reactions (e.g., pH shifts, color change)
• Failed container closure integrity over time

2. Regulatory Expectations on Packaging Evaluation

ICH Q1A(R2):

• Requires use of “market-intended container closure system” in stability studies
• Testing must reflect packaging type and configuration

FDA Guidance:

• Mandates evaluation of extractables and leachables for plastics, elastomers, and adhesives
• Expect container-closure integrity testing as part of shelf-life justification

EMA Requirements:

• Supports full material compatibility and performance data in Module 3.2.P.2 and 3.2.P.8
• Expects proof of stability in packaging across entire claimed shelf life

WHO PQ:

• Strong emphasis on protection from humidity, light, and tropical conditions
• Requires Zone IVb stability data in intended packaging

3. Types of Packaging Materials and Their Stability Impacts

Common Packaging Formats:

• HDPE Bottles: High permeability to moisture; often paired with desiccants
• Blister Packs (Alu-Alu or PVC/Alu): Light and moisture barrier varies with material
• Glass Vials and Ampoules: Inert but susceptible to surface delamination in acidic formulations
• Pre-filled Syringes: Potential silicone oil migration; interaction with elastomers
• Plastic Containers (LDPE, PET): Risk of additive leaching or API sorption

Critical Variables:

• Water vapor transmission rate (WVTR)
• Oxygen transmission rate (OTR)
• UV and visible light penetration
• Internal surface chemistry and coating compatibility

4. Designing Long-Term Stability Studies with Packaging Focus

Study Conditions:

• Real-time: 25°C ± 2°C / 60% RH ± 5%
• Intermediate: 30°C ± 2°C / 65% RH ± 5%
• Zone IVb (if applicable): 30°C ± 2°C / 75% RH ± 5%

Study Design Elements:

• Include at least three commercial batches
• Use final marketed packaging configuration (including secondary cartons and leaflets)
• Track container integrity and seal performance over time

Monitoring Parameters:

• Assay and degradation products
• Moisture content and dissolution (for solid or semi-solids)
• Leachables (if identified in extractable studies)
• pH, viscosity, and appearance (for injectables or solutions)

5. Extractables and Leachables (E&L) Studies

These are critical for plastic, elastomeric, and adhesive packaging systems. They assess whether packaging materials might release compounds into the drug product over time.

Definitions:

• Extractables: Potential compounds that may leach out under exaggerated conditions
• Leachables: Actual compounds found in the drug product under storage conditions

Study Flow:

1. Perform material compatibility and extractable profile (typically via GC-MS, LC-MS)
2. Monitor leachables in long-term stability studies using target compound list
3. Assess toxicological impact of detected leachables

6. Case Studies

Case 1: Sorption Issue in PET Bottles

An oral liquid in PET bottles showed a 10% loss in active content after 12 months at 30°C. Further testing revealed sorption of the API onto the PET walls. Packaging was changed to amber glass with rubber liner. Stability profile improved significantly.

Case 2: Leachables in Pre-Filled Syringe System

A biotech product showed appearance changes and impurity growth in syringes stored at 25°C. Investigation confirmed leaching of phenolic antioxidants from the syringe plunger. The supplier material was replaced, and extractables reduced below ICH Q3D thresholds.

Case 3: Blister Laminate Failure in Zone IV

A tablet product in PVC/Alu blisters showed failed moisture content testing in Zone IVb studies. WVTR testing revealed poor humidity barrier. Packaging was upgraded to Alu-Alu format and WHO PQ approved the updated data.

7. Reporting and Documentation

CTD Module Integration:

• 3.2.P.2: Pharmaceutical development, including container-closure system design
• 3.2.P.7: Container closure description and specifications
• 3.2.P.8.1: Summary of stability findings, including packaging interaction results
• 3.2.P.8.3: Stability data tables, E&L results, trend graphs

Tips for Regulatory Clarity:

• Use overlay plots to show data across different packaging types (if applicable)
• Provide analytical method validation for any leachable detection
• Summarize material change justifications and impact on ongoing stability

8. SOPs and Templates for Packaging Interaction Studies

Available from Pharma SOP:

• Packaging Compatibility and Stability Testing SOP
• Extractables and Leachables Study Plan Template
• Packaging System Risk Assessment Checklist
• Container Closure Integrity Testing SOP

Additional insights and regulatory guides are available at Stability Studies.

Conclusion

Packaging plays a decisive role in preserving pharmaceutical product quality over its shelf life. By proactively assessing and monitoring packaging material interactions during long-term storage—particularly under intermediate and tropical conditions—companies can avoid product failures, reduce regulatory risk, and extend market shelf life. Through a well-planned stability study and robust analytical strategy, pharmaceutical professionals can ensure their packaging systems remain as protective as intended, from first release to the final dose.